drugset
drugset / Trial / NCT04528368

Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support

NCT04528368 ↗

Phase 2 Unknown 60 enrolled D'Or Institute for Research and Education Hospital do Coracao · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The COVID-19 pandemic has been spreading continuously, and in Brazil, until August 18, 2020, there have been more than 3,359,000 cases with more than 108,536 deaths, with daily increases. The present study proposes to evaluate the efficacy and safety of using convalescent plasma for treating patients with COVID-19 pneumonia without indication of ventilatory support.

Timeline

Start
2020-12-11
Primary completion
2021-12-30
Completion
2022-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic 400 ml —

Indications

COVID-19